Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Vector-directed immunity and boosting capacity of VRP-srRNA anti-tumor vaccines.

NPJ vaccines·2026
Same author

Hemodynamics and Mid-Term Clinical Outcomes Following Valve-in-Valve TAVR With Balloon-Expandable Valves.

Circulation. Cardiovascular interventions·2026
Same author

Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer.

Nature communications·2025
Same author

Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States.

JACC. Cardiovascular interventions·2025
Same author

The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells <i>in vitro</i> and <i>in vivo</i>.

Oncotarget·2025
Same author

Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians.

CA: a cancer journal for clinicians·2025

相关实验视频

Updated: Jun 6, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K

肝细胞癌的全身疗法

Emily Kinsey1, Michael A Morse2

  • 1Department of Medicine, Division of Hematology, Oncology & Palliative Care, VCU Health, Richmond, VA, USA.

Clinics in liver disease
|November 28, 2024
PubMed
概括

肝细胞癌的全身治疗现在包括免疫检查点抑制剂. 未来的治疗重点是辅助设置和患有晚期肝功能障碍的患者.

科学领域:

  • 肝胆道癌症 肝胆道癌症
  • 医学瘤学 医学瘤学
  • 免疫治疗是一种免疫疗法.

背景情况:

  • 肝细胞癌 (HCC) 系统治疗已取得显著进展.
  • 像索拉芬尼布这样的初步治疗方法已经被新的选择所超越.
  • 目前的标准包括免疫检查点抑制剂 (ICI).

研究的目的:

  • 审查肝细胞癌全身治疗的演变情况.
  • 突出当前的治疗标准和新兴的治疗策略.
  • 讨论HCC治疗研究的未来方向.

主要方法:

  • 对肝细胞癌的全身疗法的文献综述.
  • 对当前临床试验数据和治疗指南的分析.
  • 确定正在进行和未来的研究领域.

主要成果:

  • 一线治疗已经转向ICI组合 (阿特佐利祖马布/贝瓦西祖马布,杜尔瓦卢马布/特雷梅利穆马布).
  • 即将推出的疗法包括camrelizumab/rivoceranib和nivolumab/ipilimumab. 这两种疗法将在未来推出.
  • 第二线选择仍然是多酶抑制剂或拉穆西鲁马布.
关键词:
在Atezolizumab中使用.贝瓦西祖马布 (bevacizumab) 是一种药物.卡博桑提尼布 (Cabozantinib) 是一种药物.在 Durvalumab 中使用.我不喜欢他们,我不喜欢他们.伦瓦提尼布 (Lenvatinib) 是一种药物.尼沃卢马布的使用情况这就是Tremelelimumab.

更多相关视频

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

385

相关实验视频

Last Updated: Jun 6, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

385

结论:

  • 免疫检查点封锁是第一线HCC治疗的新标准.
  • 研究正在扩展到辅助设置和患有Child-Pugh B肝功能的患者.
  • 新的检查点分子和组合策略正在调查中.